激素敏感前列腺癌的新型分子概况定义了高风险患者
Claudia Piombino1, Cecilia Nasso2, Stefania Bettelli3
1Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
研究人员在转移性激素敏感前列腺癌 (mHSPC) 患者中发现了一种遗传特征. 这种特征,包括AKT2,可能为早期激素敏感前列腺癌提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 转移性激素敏感前列腺癌 (mHSPC) 治疗缺乏预测性生物标志物.
- 目前的管理依赖于临床和病理因素.
- 在mHSPC中需要定制的治疗策略.
研究的目的:
- 在mHSPC中识别风险分层的遗传特征.
- 发现潜在的生物标志物,以指导治疗决策.
- 在激素敏感前列腺癌中探索新的治疗点.
主要方法:
- 对48名mHSPC患者的回顾性分析.
- 在瘤样本上使用了NanoString nCounter PanCancer Pathways面板.
- 根据复发时间将患者分为高临床风险组和低临床风险组.
主要成果:
- 在风险组之间确定了42个差异表达的基因.
- 在高危人群中观察到亡,PI3K和MAPK通路基因的一般过度表达.
- AKT2和其他基因显示出显著的差异性表达.
结论:
- 在mHSPC患者中发现了一种独特的遗传特征.
- 针对mHSPC,发现了包括AKT2在内的新生物标志物.
- 研究结果表明,对于激素敏感前列腺癌的潜在治疗点.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
